Indalo Therapeutics

Indalo Therapeutics, Inc.

is a preclinical-stage biopharmaceutical company established in 2016 through the merger of Antegrin Therapeutics LLC and Cascadian Therapeutics, Inc. The company is focused on developing integrin antagonist therapies for serious fibrotic diseases, including nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Headquartered primarily in St. Louis, Missouri, Indalo emphasizes its experienced team and strong intellectual property. The company's lead candidate, IDL-2965, is an oral small molecule antagonist that targets specific integrins to inhibit various stages of pathologic fibrosis. This candidate has advanced to Phase 2 trials for NASH and related fibrotic conditions. Indalo Therapeutics has raised significant funding to support its development efforts, showcasing a commitment to improving outcomes for patients with debilitating fibrotic diseases.